CEO presented yesterday at the International Cachexia Conference in Japan re: the previously released phase 2 study with our cachexia drug. Although no new information was released, this was a great audience to get the story out. As a physician, seeing 11 of 18 patients with cancer cachexia wanting to stay on the drug for quality of life, is meaningful. This drug will likely provide an unmet need for many patients.
Actually AVR118 is a small molecule antiviral used successfully in Canada for some years before it was reformulated. It also has been shown to reduce viral loads in HIV patients. It might have some value but they have had a lot of time to find a partner and haven't succeeded. The clinical trial was set up wrong by ADVR before it was acquired by OHRP.
Yes in this situation a tremendous success.
Actually this entire study was tremendously successful.
The one major downside are the endpoints that were originally aimed for by unrealistic management who truly did not understand this clinical situation/marketplace. These results are great and I will be surprised if they cannot partner this out to some large pharmaceutical company and share in the eventual profits.